Compliance and Best Practices. 2. Quick regulatory review. 3. Global Cosmetics Vigilance diagram, example of in-house operational logogram

Similar documents
February 27, Human Use. Dear Sir or Madam: new data and. responded to. United States. the United products.

Manual for Expedited Reporting of Adverse Events to DAIDS Version 2.0 January 2010

Recall Guidelines. for Chinese Medicine Products

PHARMACOVIGILANCE GLOSSARY

KEY DIFFERENCES BETWEEN THE NEW MEDICAL DEVICE AND THE OTC REGULATIONS IN EUROPE

Adverse Event Reporting Programme for Veterinary Medicines

Active TB drug-safety management & monitoring

SUSPECT ADVERSE REACTION REPORT

Research & Development. J H Pacynko and J Illingworth. Research, pharmacy and R&D staff

FoodDrinkEurope Position on GLP studies

SAE håndtering i protokol CC MM-001

CHAPTER 4 POST-MARKETING SURVEILLANCE OF DRUGS

NEHSNORTH EASTERN HEALTH SPECIALISTS

Good Laboratory Practice. EU-Serbia screening meeting Brussels, 19 June 2014

Drugs Regulatory Unit Ministry of Health PHARMACOVIGILANCE GUIDELINES

ORDER of the Minister of Health No. 269/2017 of 14 March 2017 on mandatory provision of medicinal product adequate and continuous supplies

Counterfeit Medicinal Products. FINLAND Roschier, Attorneys Ltd.

Adverse Events Monitoring (aka Pharmacovigilance)

Update on Australian regulatory framework for medical devices

RESULTS AT A GLANCE. FDA Oversight of Tobacco Manufacturing Establishments. HHS OIG Data Brief August 2017 OEI

MOTION FOR A RESOLUTION

The Telecommunications Act of 1996

Guidelines to Commission Regulation (EU) No 655/2013. laying down common criteria for the justification of claims used

SUSPECT ADVERSE REACTION REPORT

Adult Patient Information and Consent Form

EDQM and European Pharmacopoeia: State-of-the-art Science for Tomorrow s Medicines

PROFICIENCY TESTING POLICY

SUSPECT ADVERSE REACTION REPORT

CERTIFICATION COURSES Information and Application

Market surveillance of medical devices

Clinical Study Synopsis for Public Disclosure

Clinical Study Report SLO-AD-1 Final Version DATE: 09 December 2013

Lead-up to REACH Pre-Registration

Clinical Study Synopsis

Have a Voice in Your Choice!

Medication Information for Parents and Teachers

Serious Adverse Event (SAE) Form Clinical Trials

EU Regulatory Requirements Update, the latest news and developments. Hans-Heiner Junker TÜV SÜD Product Service GmbH October 2013

NEHSNORTH EASTERN HEALTH SPECIALISTS

LEAF Marque Assurance Programme

COMPETENT AUTHORITY (UK) MEDICAL DEVICES DIRECTIVES GUIDANCE NOTES FOR MANUFACTURERS OF DENTAL APPLIANCES

PROPECIA is prescribed for individuals with male pattern baldness.

Guidelines for Product Recall or Withdrawal

PHYSIOTHERAPY ACT AUTHORIZATION REGULATIONS

Medication Information for Parents and Teachers

SUSPECT ADVERSE REACTION REPORT

Introduction. Doc-Biocides-2002/01 Version

Table of Contents. Injectable Gel with 0.3% Lidocaine

We get your personal data from the following sources (examples detailed below are not exhaustive):

(Adopted by the Committee of Ministers on 19 January 2011 at the 1103rd meeting of the Ministers Deputies)

National nutrivigilance scheme

POSSIBLE REVISION OF THE TOBACCO PRODUCTS DIRECTIVE 2001/37/EC PUBLIC CONSULTATION DOCUMENT

SOP 17 BLOOD BANK. 3. Overall Responsibility: Blood Bank In-Change/Pathologist.

Planning For The FDA s 'Deeming Rule' For E- Cigarettes

Quality Management System Certification. Understanding Quality Management System (QMS) certification

MS Society Safeguarding Adults Policy and Procedure (Scotland)

PATIENT INFORMATION LEAFLET. Naseptin Nasal Cream chlorhexidine dihydrochloride and neomycin sulfate

Urgent field safety notice

SUSPECT ADVERSE REACTION REPORT

Medication Information for Parents and Teachers

Pharmacovigilance Methods and Post-Authorisation Safety Studies

POLICIES AND PROCEDURES

APOC-5FU Cream Fluorouracil

Consumer Perception of Thresholds

GUIDANCE DOCUMENTS CONTAINING THE COMMON PROVISIONS ON THE CONDUCT OF GCP INSPECTIONS BY COMPETENT AUTHORITIES OF THE DIFFERENT MEMBER STATES

Use of abatacept in rheumatoid arthritis - patient information

The Chartered Society of Physiotherapy Complaints Procedure

Regulatory scientific significance of Japan s ADR relief system

HUMAN PHOTOTOXICITY AND PHOTOALLERGENICITY TEST. April, 2006

Enhanced Continuing Professional Development and Personal Development Planning

PROTECT YOURSELF FROM TYPE I ALLERGIES.

RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS

HELP RESTORE A MORE YOUTHFUL LOOK

patients and family NEMOS for treatment of epilepsies

Draft Guidelines on the Sale and Supply of Non- Prescription Medicinal Products from a Retail Pharmacy Business

Reports of Adverse Drug Reactions, etc. of Pharmaceuticals

Lidocaine PATIENT INFORMATION GUIDE

Medical Devices. UKRAINE Magisters

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use

SUSPECT ADVERSE REACTION REPORT

Diphencyprone (DPC) treatment for Alopecia Areata

HUMAN REPEAT INSULT PATCH TEST

ADT Booster (ay-dee-tee boo-ster)

Serious Adverse Event (SAE) Form Clinical Trials

Managing Allergens within a manufacturing context. Helen Brown CampdenBRI Chipping Campden

FSE s approach to novel foods BELFRIT List

PUBLIC CONSULTATION DOCUMENT

TOBACCO PRODUCT OR MEDICAL PRODUCT?

CONSENT FOR FACE-LIFT SURGERY (RHYTIDECTOMY)

RECERTIFICATION PROGRAMME FOR CONTINUING PROFESSIONAL DEVELOPMENT OF OPTOMETRISTS

A world leader in allergy immunotherapy

Public Assessment Report for a Traditional Herbal Medicinal Product for Human Use

I_HeERO Ostrava 30 th October Andy Rooke Technical Implementing Officer I_HeERO ERTICO

Overview of thoughts on skin testing

PATIENT STUDY INFORMATION LEAFLET

Establishing Enforcement Remit

8.0 ADVERSE EVENT HANDLING

Understanding Adverse Events

Other EU Activities Contributing to Harmonization of Labeling

Self-declaration of Belgium regarding the recovery of the HPAI free status in poultry

Transcription:

Personal Care Products Council Safety seminar Oct. 27, 2011 Cosmetics Vigilance in the EU www.iris-vigilance.com Compliance and Best Practices 1. Introducing IRIS 2. Quick regulatory review 3. Global Cosmetics Vigilance diagram, example of in-house operational logogram 4. Focus on SUEs (Serious Undesirable Effects) 5. Case studies 6. EU Competent Authorities reports in 2010 7. Conclusion 2 1

Introducing IRIS Service provider engaged by Brands to manage their consumers health-related complaints (IRIS Call center) 1st company to offer Cosmetovigilance services (1992) Unipex group s affiliate (www.unipex.com) Expertise in dermatology and allergy Linguistic skills (covering approx. 50 countries worldwide) Network of +1500 physicians deployed across the EU, Asia Member of Cosmetics Vigilance Task-Force group (FEBEA) CURRENT & UPCOMING COSMETIC REGULATIONS IN EUROPE MAIN COSMETICS VIGILANCE OBLIGATIONS - Directive 76/768/EEC : Register Undesirable Effects to the Product Information File and make these information easily accessible to local competent authorities and to the Public - Regulation (EC) 1223/2009 : Notify local competent authorities about any Serious Undesirable Effect occurring in Europe (applicable as from July 11, 2013) 4 articles addressing Post Market Surveillance in Reg. EC 1223/2009 Art. 10 & 11 (cosmetic product safety report appendix 1, section 9- to be kept up-to-date with CV data, Product Information File content includes this product safety report) Art. 21 (Access to information for the public) Art. 23 (Communication of serious undesirable effects) 2

Mail, Fax Telephone Consumers, Health Professionals, Authorities Inform the person responsible for placing the product on the market (manufacturer, distributor) about a health-related complaint E-mail Global PMS process in the EU Direct contact Undesirable event (alleged) Criteria requested to confirm a case => - Identification of the cosmetic product(s) - Identification of the notifier or consumer - Description of the undesirable event - Date of onset (undesirable event) Undesirable event (confirmed) Actions Step 1 : Data collection & analysis Step 2 : Assess the causality Tools 1. Standard questionnaire (+/- data) 2. Decision tree Undesirable effect Causality assessments = VERY LIKELY or LIKELY (??) Registration to the Product Information File Information to the public (on request) Other causality assessments To be kept May be reviewed (occurrence) Summarized step-by-step actions Upon receipt of an Undesirable Event Action 1 => Register the case under a unique reference and indicate the date of receipt Action 2 => Fill out a standard questionnaire or send this questionnaire over to the consumer (mail/e-mail) A standard Undesirable Event Questionnaire should at least contain : Consumer s identification & contact details Product identification Description of the Undesirable event Chronology (dates of onset, of disappearance) Information about associated factors (concomitant use of other cosmetics ) Consequences of the UE (is there any criterion of seriousness? ) Action 3 => Check if the data gathered are sufficient to confirm the Undesirable Event into an Undesirable effect Action 4 => Complementary, data deemed necessary? if not directly assess the causal relationship product/ue Next actions => Closing process (anonymize personal data), Diffusion within the company, Archiving, Data compiling & interpretation 3

In-house Operational Logogram (example) A Standard Operation Procedure for UEs management should detail What are these services requested to do then, when (timeframe) and how Undesirable Event Questionnaire / script 4 criteria : -Pdct identified -Cons./Not. Identified -UE described -Date of onset In-house Operational Logogram (example) Case management (which are the conditions that request further documented data ) Decision tree 4

In-house Operational Logogram (example) UE is NOT confirmed Closing process, Diffusion list, Personal data anonymization, Archiving, Data compiling Example of a decision tree (Colipa Guidelines, 2005) Symptoms It is important to note that a causality assessment can only be performed if there is sufficient information on the case history (in particular symptoms and chronology). Chronology compatible Chronology not clearly compatible or unknown not performed, or not performed or Not clearly attributable Questionable Likely Very likely Likely Questionable Unlikely Symptoms : if the symptoms are not evocative (i.e. not suggestive of the product effect) the final level of causal relationship is decreased by one degree (very likely to likely, likely to questionable,questionable to unlikely) Compatible chronology : A time sequence between product use and the occurrence of symptoms as well as between stopping product use and clearing up of the symptoms which is plausible from a viewpoint and can be reasonably anticipated for this kind of product use and undesirable event. If the chronology is not compatible the causal relationship is excluded. Rechallenge : Controlled re-exposure to the product, considering the exposure conditions of the time when the event occurred. 5

Focus on SUEs / Definitions, Criteria To be noted : Serious (consequences of UE) Severe (intensity of UE) Definition (cf. Regulation 1223/2009) Temporary or permanent functional incapacity Disability Hospitalisation Information to provide Duration, +/- Medical certificate, +/- expert evaluation % of disability, +/- Medical certificate, +/- expert evaluation Duration, hospital address, treatments Congenital anomalies Detected during pregnancy or after delivery, +/- expert evaluation Immediate vital risk Treatment, specific measures Death Date, diagnosis, +/- death certificate Focus on SUEs / Reporting procedure for SUEs received by RP or Distributor Initial receipt 20 calendar days Report to local Comp. Authority Level of data is complete No Yes Report mentions «Initial» and «Final» + Causality assessment Report mentions «Initial» New, relevant information No Yes Report mentions «Final» + Causality assessment Report mentions «Follow Up» OR «Final» + Causalilty assessment 6

Focus on SUEs / Notification Form (for RP, Distrib.) To date, consist of a 3-page form with 13 sections to fill out (if info available) Case report Company Seriousness criteria Primary reporter End user Suspected product Description of SUE (type, location) Outcome of SUE Relevant underlying conditions ( condition, treatments ) Relevant history Case management Complementary (allergy tests ) Summary Incriminated pdct : Hair balsam Consumer : 8-year old girl Country : Denmark Case study#1 Description of UE: Itching, swelling, redness and spots in scalp + behind the ears Use of the pdct: 1 st purchase. 1 unique use Chronology: 12 hours after use. Took 1 week to settle down Consequences: Advice taken from GP and self-medication with topical dermocorticoids Medical Investigation: Positive Patch-test to finished pdct. PT with detailed ingredients showed to 1 ingredient Diagnosis: Allergic contact dermatitis 7

Case study#1_hair balsam Chronology compatible Symptoms Symptoms are evocative It is important to note that a causality assessment can only be performed if there is sufficient information on the case history (in particular symptoms and chronology). Chronology not clearly compatible or unknown not performed, or not performed or Questionable Likely Very likely Likely Questionable Unlikely Symptoms : if the symptoms are not evocative (i.e. not suggestive of the product effect) the final level of causal relationship is decreased by one degree (very likely to likely, likely to questionable,questionable to unlikely) Compatible chronology : A time sequence between product use and the occurrence of symptoms as well as between stopping product use and clearing up of the symptoms which is plausible from a viewpoint and can be reasonably anticipated for this kind of product use and undesirable event. If the chronology is not compatible the causal relationship is excluded. Rechallenge : Controlled re-exposure to the product, considering the exposure conditions of the time when the event occurred. Incriminated pdct : Lip care (balsam) Consumer : 47-year old women Country : France Case study#2 Description of UE: Feeling of swollen lips (but no visible signs). During the 3 rd week of use, she noticed the skin of her lower lip was cracking, just in the right corner. Use of the pdct: 1 st purchase. Used for approx. 3 weeks with intermittent discontinuations. Chronology: Immediate after first application. Use continued over 10 days, then stopped for 3 days and reused until cracks appeared Consequences: Attended a consultation with her GP Medical Investigation: No Diagnosis: Labial herpes 8

Case study#2_lip care Symptoms It is important to note that a causality assessment can only be performed if there is sufficient information on the case history (in particular symptoms and chronology). Chronology compatible Chronology not clearly compatible or unknown not performed, or not performed or Questionable Likely Very likely Likely Questionable Unlikely Reason : labial herpes is a viral infection which cannot be caused by a cosmetic Symptoms : if the symptoms are not evocative (i.e. not suggestive of the product effect) the final level of causal relationship is decreased by one degree (very likely to likely, likely to questionable,questionable to unlikely) Compatible chronology : A time sequence between product use and the occurrence of symptoms as well as between stopping product use and clearing up of the symptoms which is plausible from a viewpoint and can be reasonably anticipated for this kind of product use and undesirable event. If the chronology is not compatible the causal relationship is excluded. Rechallenge : Controlled re-exposure to the product, considering the exposure conditions of the time when the event occurred. Incriminated pdct : Facial skin care (anti-ageing) Consumer : 42-year old women Country : Italy Case study#3 Description of UE: Tingling sensations and itching on the entire face, together with red blotches and papules localized on right cheek only. Use of the pdct: 1 st purchase. Daily applications during 10 consecutive days. Chronology: UE occurred after 4 days. Product continued for a further 6 days before definitive discontinuation. Skin returned to normal after 6 weeks Consequences: None Medical Investigation: No 9

Case study#3_skin care Symptoms It is important to note that a causality assessment can only be performed if there is sufficient information on the case history (in particular symptoms and chronology). Chronology compatible Symptoms are not evocative (visible signs localized on 1 cheek whereas pdct applied to the entire face) Chronology not clearly compatible or unknown 6 weeks to clear up after the pdct was discontinued not performed, or not performed or Questionable Likely Very likely Likely Questionable Unlikely Symptoms : if the symptoms are not evocative (i.e. not suggestive of the product effect) the final level of causal relationship is decreased by one degree (very likely to likely, likely to questionable,questionable to unlikely) Compatible chronology : A time sequence between product use and the occurrence of symptoms as well as between stopping product use and clearing up of the symptoms which is plausible from a viewpoint and can be reasonably anticipated for this kind of product use and undesirable event. If the chronology is not compatible the causal relationship is excluded. Rechallenge : Controlled re-exposure to the product, considering the exposure conditions of the time when the event occurred. EU Competent Authorities reports in 2010 1. FRANCE 219 UEs notified, 13% of serious cases Population : women (71%), men (14%) and children (15%) Main cosmetic categories : Sun care, Body care (l-o), F&E makeup + removers Notifications by Health Professionals, health institutions (92%), Industry (6%) 2. THE NETHERLANDS 1250 UEs notified, no information about serious cases Population : women (90%), hardly any report involving babies/young children Main cosmetic categories : Face care, Hair care and Makeup Notifications by consumers (hotline, internet questionnaire) + Health Prof. 3. NORWAY 96 UEs notified between 2008-2010. No information about serious cases Population : women (83%), Children up to 9 yrs old (7%) Main cosmetic categories : Moisturizers, Sun care and Hair dyes, bleaches Notifications made by Health Professionals 10

FRANCE, 10 days ago Conclusion To properly handle UE complaints, a company should 1. Develop an internal SOP (Standard Operation Procedure) to organize this activity 2. Inform and train all the people who may be involved in the process (distributors, in-house staff ) about what they have to do, how and when 3. Audit the system to check it duly works (ex. false cases) 4. Ensure the causality assessment is done by someone who is experienced and has appropriate professional background => reliability of the results THANK YOU 11